Abliva AB Interim Report January – September 2020
KL1333 is on its way to pivotal clinical study - Pivotal study planned for the second half of 2021
Magnus Persson leaves the Board of Directors of Abliva AB to focus on role as founding partner at Eir Ventures
Abliva AB (Nasdaq Stockholm: ABLI) today announces that Magnus Persson is leaving the company's Board of Directors at his own request, to focus on his role as founding Partner at Eir Ventures, a recen ...
Abliva completes the directed issue of MSEK 20 to Hadean Ventures
On April 22, 2020, the Board of Directors of Abliva AB (publ) ("Abliva" or the "Company") resolved, supported by the authorization granted at the Annual General Meeting on April 25, 2019, on a directe ...
Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) today on 20 May 2020 held its Annual General Meeting (AGM). A summary of the resolutions follows.
Interim Report January-March 2020
Important events, first quarter (Jan – Mar 2020) NeuroVive proposes a 90 percent guaranteed rights issue of MSEK 74 in order to ensure that the Company has financial resources for its prioritize ...
NeuroVive’s Nomination Committee amends its proposal to the 2020 Annual General Meeting
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) today announced that the Company's Nomination Committee in its proposal to the Annual General Meeting May 20, 2020, added a proposal regarding an ad ...
Publication of supplementary prospectus related to NeuroVive’s rights issue
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has prepared a supplementary prospectus (the “Supplementary Prospectus”) to the prospectus that was approved and regi ...
Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ)
The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 10 a.m. on Wednesday, 20 May 2020 at Medicon V ...
NeuroVive publishes prospectus and new financial information included in the prospectus in connection with forthcoming rights issue
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has in connection with the forthcoming issue of shares with preferential rights for existing shareholders, announced ...
NeuroVive Pharmaceutical AB (publ): report from EGM
Today, 17 March 2020, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”). A summary of the resolutions follows. The resolution was passed wi ...
NeuroVive Pharmaceutical AB Year End Report January – December 2019
Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroVi ...
Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)
The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at 3 pm on Tuesday 17 March 2020 at Medicon Village, Scheelevägen 2, ...